GSK vs PRTC
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 09, 2026
GSK
PRTC
Investment Advisor Scores
PRTC
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GSK | PRTC | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 20.79 | 0 | Tie |
| PEG Ratio | 103.9082 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 5.3% | -38.2% | GSK |
| Earnings Growth | -69.5% | 61.5% | PRTC |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 47.1/100 | 50.6/100 | PRTC |
| Profit Margin | 14.5% | 0.0% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | BUY | HOLD | GSK |
Relative Price Performance (Last 90 Days)
Current Technical Phase
GSK
MarkupPrice above SMA50, rising 50-day trend (0.7% over 20 days), RSI 56
PRTC
NeutralMixed signals - no dominant trend phase, RSI 52
Fundamentals Snapshot
| Metric | GSK | PRTC |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 10.3 | 0.0 |
| Trailing P/E | 16.3 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | -0.4% |
| Gross Margin | 0.7% | -11.1% |
| Operating Margin | 0.3% | -18.0% |
| EPS | 3.21 | -4.60 |
| Dividend Yield | 0.04% | — |